Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids?. (3rd September 2017)

• Record Type: Journal Article
• Authors: Harlander, Matevz; Barrecheguren, Miriam; Turel, Matjaz; Miravitlles, Marc
• Is Part Of: COPD. Volume 14:Number 5(2017)
• Page Start: 465
• Page End: 468
• Publication Date: 2017-09-03
• Subjects: COPD -- GOLD -- inhaled corticosteroids -- withdrawal; Lungs -- Diseases, Obstructive -- Periodicals; 616.24
• DOI: 10.1080/15412555.2017.1342233
• Languages: English
• ISSNs: 1541-2555

Abstract

ABSTRACT: Inhaled corticosteroids (ICSs) are the cornerstone of the treatment of asthma, but their role in COPD is limited. Several guidelines recommend their use in patients with severe airflow limitation, frequent exacerbations and asthma-COPD overlap (ACO), while the previous GOLD document recommended ICS for patients with high risk of exacerbations and a high level of symptoms (group D). Following the changes in the GOLD document 2017 update, in which impaired lung function is no longer considered as a determinant of exacerbation risk, a high number of COPD patients can now be labeled as group B (low risk of exacerbations and high level of symptoms) instead of D, and hence, no longer fulfill the indication for ICS. Since long-term therapy with ICS can entail secondary effects, the withdrawal of this treatment should be considered in this group of patients. In this article, we summarize the evidence for discontinuation of ICS in this subgroup of patients and provide suggestions for clinicians on the appropriate use on ICS in patients moving from D to B.